It often starts quietly. A bit of fatigue, a sense that something feels off, but nothing alarming enough to trigger concern.
Now, reporting by LadBible, based on global research, highlights how a largely overlooked liver condition is spreading rapidly — with experts warning it could affect nearly 1.8 billion people by 2050.
A growing threat
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is increasingly being identified as a major global health issue, despite not being linked to alcohol use.
According to findings from the Global Burden of Disease study published in The Lancet Gastroenterology & Hepatology, around 1.3 billion people are already affected worldwide, marking a sharp rise over recent decades.
Also read: New injection could change arthritis treatment
Researchers warn that number could climb to 1.8 billion by 2050, driven by rising obesity rates, type 2 diabetes and more sedentary lifestyles.
The condition develops when excess fat builds up in the liver, gradually affecting how the organ functions.
Hidden symptoms
One of the biggest concerns is how easily MASLD can go unnoticed. Many people show no clear signs in the early stages.
When symptoms do appear, they are often subtle and may include:
Also read: Food authority advises against new potatoes for infants
- Ongoing fatigue
- A general sense of feeling unwell
- Discomfort in the upper right side of the abdomen
Because these warning signs are vague, the condition is often discovered incidentally during tests for other health issues.
If untreated, the disease can progress, leading to inflammation, scarring and, in severe cases, cirrhosis, liver failure or cancer.
Prevention focus
Health authorities are increasingly focusing on prevention as cases continue to rise globally.
Guidance from the NHS recommends maintaining a balanced diet, increasing physical activity and managing weight to lower the risk.
Also read: How protein powder can affect your body if you take it every day
At the same time, emerging research suggests that certain GLP-1 medications, commonly used for diabetes and weight loss, could offer potential benefits in treating MASLD.
LadBible reports that experts are calling for greater awareness of the condition, particularly because it challenges common assumptions about liver disease being primarily linked to alcohol use.
Also read: How raisins can affect your body if you eat them every day
This article is made and published by Mie Hermansen, who may have used AI in the preparation.